Cai Shaohang, Liao Guichan, Yu Tao, Gao Qiqing, Zou Lirong, Zhang Huan, Xu Xuwen, Chen Juanjuan, Lu Aili, Wu Yingsong, Li Baisheng, Peng Jie
Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Department of Infectious Diseases, Shunde Hospital Affiliated to Southern Medical University, Shunde, China.
J Med Virol. 2022 Sep;94(9):4224-4233. doi: 10.1002/jmv.27872. Epub 2022 May 28.
We aimed to analyze the efficacy and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV (PLWH). A total of 143 PLWH and 50 healthy individuals were included in this study. A commercially available magnetic chemiluminescence enzyme immunoassay kit was used to detect serum IgG and IgM antibodies against SARS-CoV-2. Serum levels of SARS-CoV-2-specific IgG were significantly higher in the control group than in the PLWH group (p = 0.001). Overall, 76% of individuals in the control group were detected with seropositivity IgG against SARS-CoV-2 compared to 58% in the PLWH group (p = 0.024). In PLWH with IgG seropositivity, CD4+ T-cell counts before antiretroviral therapy (ART) was higher (p = 0.015). Multivariable analysis indicated that CD4+ T cells at IgG detection (odds ratio [OR] = 1.004, p = 0.006) and time after vaccination (OR = 0.977, p = 0.014) were independently associated with seropositivity IgG against SARS-CoV-2 in PLWH. Neutralizing antibody (nAb) titers in PLWH against wild-type SARS-CoV-2 were similar to those in the control group (p = 0.160). The proportion of seropositive nAbs against wild-type SARS-CoV-2 was also similar (95% in the control group vs. 97% in the PLWH group, p = 0.665). Similar results were obtained when nAb was detected against the delta variants with similar titers (p = 0.355) and a similar proportion of seropositive nAbs were observed (p = 0.588). All the side effects observed in our study were mild and self-limiting. The inactivated COVID-19 vaccine appears to be safe with good immunogenicity in Chinese PLWH.
我们旨在分析一种新型冠状病毒灭活疫苗对艾滋病毒感染者（PLWH）的有效性和安全性。本研究共纳入了143名艾滋病毒感染者和50名健康个体。使用市售的磁化学发光酶免疫分析试剂盒检测针对新型冠状病毒的血清IgG和IgM抗体。对照组中新型冠状病毒特异性IgG的血清水平显著高于艾滋病毒感染者组（p = 0.001）。总体而言，对照组中76%的个体检测到针对新型冠状病毒的IgG血清阳性，而艾滋病毒感染者组为58%（p = 0.024）。在IgG血清阳性的艾滋病毒感染者中，抗逆转录病毒治疗（ART）前的CD4 + T细胞计数较高（p = 0.015）。多变量分析表明，IgG检测时的CD4 + T细胞（比值比[OR] = 1.004，p = 0.006）和接种疫苗后的时间（OR = 0.977，p = 0.014）与艾滋病毒感染者中针对新型冠状病毒的IgG血清阳性独立相关。艾滋病毒感染者针对野生型新型冠状病毒的中和抗体（nAb）滴度与对照组相似（p = 0.160）。针对野生型新型冠状病毒的nAb血清阳性比例也相似（对照组为95%，艾滋病毒感染者组为97%，p = 0.665）。当检测针对具有相似滴度的德尔塔变体的nAb时，也获得了相似的结果（p = 0.355），并且观察到nAb血清阳性比例相似（p = 0.588）。我们研究中观察到的所有副作用均为轻度且具有自限性。在中国的艾滋病毒感染者中，新型冠状病毒灭活疫苗似乎安全且具有良好的免疫原性。
